4.5 References
［1］Breast Cancer Professional Committee of China Cancer Association，Guidelines and Norms for Breast Cancer Diagnosis and Treatment of China Cancer Association（2017 edition）China Journal of Cancer，2017，27（9）：695-760.
［2］Aebi S，Gelber S，Anderson S），et al.Chemotherapy for isolated locoregional recurrence of breastcancer（CALOR）：a randomised trial.Lancet Onco，2014，15（2）：156-163.
［3］Arvold ND，Taghian AG，Niemierko A，et al.Age，breast cancer subtype approximation and local recurrence after breast-conservinag therapy.J Clin Oncol，2011，29（29）：3885-3891.
［4］Boileau JF，Poirier B，Basik M，et al.Sentinel nodetopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer：the SN FNAC study.J Clin Oncol，2015，33：258-264.
［5］Boughey JC，Suman VI，Mittendorf EA，et al.Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071（Alliance）.Ann Surg，2015，261（3）：547-552.
［6］Clarke M，Collins R，Darby S，et al.Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival：an overview of the randomized trials.Lancet，2005，366（9503）：2087-2106.
［7］Coates AS，Winer EP，Goldhirsch A，et al.Tailo-ring therapies-improving the management of early breast cancer.St.Gallen International Expert Comsensus on the primary therapy of early breast cancer 2015.Ann Onco1，2015，26：1533-1546.
［8］Donker M，van I enthovenG，Straver ME，et al.Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer（EORTC 10981-22023 AMAROS）.a randomised，multicentre，opemlabel，phase 3 non-inferiority trial.Lancet Oncol，2014，15（12）：1303-1310.
［9］Ferlay J，Soerjomataram I，Ervik M，et al.GLOEXAN 2012v1.0，cancer incidence and mortality world-wide：IARC Cancerbase No 11.Int J Cancer，2014，136（5）：p359-p386.
［10］Fisher B.Anderson S，Bryant J，et al.Twenty-year follow-up of a randomized trial comparing total mastectomy，lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer.N Engl J Med 2002，347：1233-1241.
［11］Van Dongen JA，Voogd AC，Fentiman IS，et al.Longterm results of a randomized trial comparing breast-conserving therapy with mastectomy.European Organization for Research and Treatment of Cancer 10801 trial.J Natl Cancer Inst 2000，92：1143-1150.
［12］Crile G.The evolution of the treatment of breast cancer In：Breast Cancer：Controversies in Management.Futura Publishing Co.Armonk，NY，USA，1994.
［13］Degenshein GA，Ceccareli F.The history of breast cancer surgery.Early beginnings to Halsted.Breast，1977，3：28-35.
［14］Lewison EF.The surgical treatment of breast cancer：anistorical and collective review.Surgery，1953，34（904-953）.
［15］Robinson JO.Treatment of breast cancer throughout the ages.American Journal of Surgery，1986，151：317-333.
［16］Jacobson JA，Danforth DN，Cowan KH，et al.Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and Ⅱ breast cancer.N Engl J Med 1995，332：907-911.
［17］Morrow M，Strom EA，Bassett I W，et al.Standard of breast conserving therapy in the management of invasive breast cancer.CA Cancer Clin J 2002，52：277-300.
［18］Torresan RZ，dos Santos CC，Okamura H，et al.Evaluation of residual glandular tissue after skin-sparing mastectomies.Ann Surg Oncol 2005，12：1037-1044.
［19］Hynes DM，Weaver F，Morrow M，et al.Breast cancer surgery trends and outcomes：results from a National Department of Veterans Affairs study.J Am Coll Surg 2004，198：707-716.
［20］El-tamer MB，Ward BM，Schifftner T，et al.Morbidity and mortality following brreast cancer surgery in women national benchmarks for standard of care，Arnn Surg 2007，245：665-671.(https://www.daowen.com)
［21］Pogson CJ，Adwani A Ebbs SR Seroma following breast cancer surgery.Eur J Surg Oncol 2003，29：711-717.
［22］Stevens P，Dibble S，Miastowski C.Prevalence，charac-teristics，and impact of postmastectomy pain syndromean investigation of women experiences.Pain 1995，61：6168.
［23］Vitug AF，Newman LA Complications in breast surgery.Surg Clin North Am 2007，87：431-451.
［24］Intra M.Garcia-etieene CA，Renne G，et al.When sentinel lymph node is intramammary.Ann Surg Oncol 2008，15：1304-1308.
［25］Giuliano AE.Mapping a pathway for axillary staging：a personal perspective on the current status of sentinel lymph node dissection for breast cancer.Arch Surg 1999，134：195-199.
［26］Veronesi U.De Cicco C，Galimberti VE，et al.A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.Ann Oncol 2007，18：473-478.
［27］Wahl RL，Siegel BA，Coleman RE，et al.Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer：a report of the staging breast cancer with PET study group.J Clin Oncol 2004，22：277-285.
［28］Giuliano AE，Jones RC，Brennan MB，et al.Sentinel lymphadenectomy in breast cancer.J Clin Oncol 1997，15：2345-2350.
［29］Halsted WS.The results of radical operations for the cure of carcinoma of the breast.Ann Surg 1907，46：1.
［30］Martelli G，Boracchi P，De Palo M，et al.A randomized trial comparing axillary dissection to no axillary dissection in older patients with TINO breast cancer：results after 5 years of follow-up.Ann Surg 2005，242：1-6.
［31］Guller U，Nitzsche EU，Chirp U，et al.Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose：not yet！Breast Cancer Res Treat 2002，71：171-173.
［32］Giuliano AE，Ballman KV，Mccall L，et al.Efect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis.The ACOSOG Z0011（Alliance）randomized clinical trial JAMA，2017，318（10）：918-926.
［33］Giuliano AE，Hunt KK，Balman KV，et al.Axillary dissection vs no axillary dissection in women with Invasive breast cancer and sentinel node metastasis：a randomized clinical trial.JAMA 2011，305（6）：569-575.
［34］Li JJ，Shao ZM.Enendocrine therapy as adjuvant or neoadjuvant therapy for breast cancer：selecting the best agents，the timing and duration of treatment.Chin Clin Oncol，2016，5（3）：40.
［35］Kuehn T，Bauerfeind I，Fehm T，et al.Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy（SENTINA）：a prospective，multicentre cohort study.Lancet Oncol，2013，14：609-618.
［36］Litiere S，Werutsky G，Fentiman IS，et al.Breast conserving therapy versus mastectomy for stageⅠ-Ⅱ breast cancer：20 year follow-up of the EORTC 10801 phase 3 randomised trial.Lancet Oncol 2012，13（4）：412-419.
［37］Moran MS，Schnitt SJ，Giuliano AE，et al.Society of Surgical Oncology-American Society for Radiation Oncology consensus guladeline on margins for breast conserving surgery with whole-breast irradiation in stages Ⅰ and Ⅱ invasive breast cancer.J Clin Oncol 2014，32（14）：1507-1515.
［38］Perez EA，Suman VJ，Davidson NE，et al.Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.J Clin Oncol，2011，29（34）：491-4497.
［39］Veronesi U，Luini A，del Vecchio M，et al.Radiotherapy after breast-preserving surgery in womenth localized cancer of the breast.N Engl J Med，1993，328（22）：1587-1591.